Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Enzalutamide after docetaxel for mCRPC: evaluation by the Italian Named Patient Program

Orazio Caffo, MD, of the Santa Chiara Hospital, Trento, Italy, shares insights on the recent evaluation of the efficacy and safety data of enzalutamide after docetaxel for advanced metastatic castration resistant prostate cancer, performed by the Italian Named Patient Program. This interview was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Transcript (edited for clarity)

In this moment, in Italy, it is possible to use enzalutamide in M0 CRPC patients. But I think this is a pretty changing condition which produces great effects following treatment. The main in terms of castration-resistant prostate cancer patients because I think that all conditions where new androgen receptor targeting agents such as

In this moment, in Italy, it is possible to use enzalutamide in M0 CRPC patients. But I think this is a pretty changing condition which produces great effects following treatment. The main in terms of castration-resistant prostate cancer patients because I think that all conditions where new androgen receptor targeting agents such as enzalutamide or also apalutamide in the next future. It changes our approach in the castration-resistant prostate cancer patients because the main problem is the possibility of cross-resistance between the two different new hormonal agents.

In other terms, I don’t know, in this moment if the abiraterone works after enzalutamide given in an M0 patients when the patients develop the castration-resistant disease. At the same time, we don’t know what is the rate of activity of docetaxel or cabazitaxel when these patients became castration-resistant. Because I think all changes we made in terms of therapeutic approach in castration-sensitive disease, these are related to a change in the biology of the disease. And at this moment we don’t know what happened when the disease became castration-resistant.

Read more...